Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-25-123677
Filing Date
2025-05-21
Accepted
2025-05-21 08:42:50
Documents
19
Period of Report
2025-07-03

Document Format Files

Seq Description Document Type Size
1 DEF 14A d921291ddef14a.htm   iXBRL DEF 14A 675511
6 GRAPHIC g921291dsp005.jpg GRAPHIC 193715
7 GRAPHIC g921291dsp006.jpg GRAPHIC 130818
  Complete submission text file 0001193125-25-123677.txt   2171338

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA tcrt-20241231.xsd EX-101.SCH 3478
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE tcrt-20241231_def.xml EX-101.DEF 2544
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tcrt-20241231_lab.xml EX-101.LAB 2602
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tcrt-20241231_pre.xml EX-101.PRE 1645
22 EXTRACTED XBRL INSTANCE DOCUMENT d921291ddef14a_htm.xml XML 132785
Mailing Address 2617 BISSONNET ST SUITE 233 HOUSTON TX 77005
Business Address 2617 BISSONNET ST SUITE 233 HOUSTON TX 77005 (346) 355-4099
Alaunos Therapeutics, Inc. (Filer) CIK: 0001107421 (see all company filings)

EIN.: 841475642 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-33038 | Film No.: 25970987
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)